Arbium Plus Tablet 100 mg + 12.5 mg

Arbium Plus Tablet, manufactured by Asiatic Laboratories Ltd, combines Losartan Potassium (100 mg) and Hydrochlorothiazide (12.5 mg) in a single tablet. This combined antihypertensive medication is priced at ৳10.00 per unit, with strips of 10 tablets available for ৳100.00. It effectively treats hypertension and reduces stroke risk in patients with left ventricular hypertrophy.

The dual-action formula targets blood pressure regulation through complementary mechanisms. Losartan blocks angiotensin II receptors, preventing vasoconstriction, while Hydrochlorothiazide promotes diuresis. This combination enhances efficacy compared to monotherapy, achieving optimal results within 3 weeks. The maximum recommended dose is 100/25 mg once daily, adjusted based on patient response and age.

Storage requires temperatures below 30°C, with strict precautions to keep it away from children. Common side effects include dizziness, electrolyte imbalance, and mild gastrointestinal issues. Severe reactions like angioedema or hyperkalemia are rare but require immediate medical attention. Avoid use during pregnancy due to fetal risks.

For detailed information on the Losartan + Hydrochlorothiazide therapeutic class, consult healthcare providers. This cost-effective therapy offers a practical solution for long-term hypertension management, supported by Asiatic Laboratories’ quality standards.

Standard adult dose: 50/12.5 mg once daily. May increase to 100/25 mg after 3 weeks based on blood pressure response. Elderly patients should avoid 100/25 mg as initial dose. Renal impairment (CrCl >30 ml/min) requires no dose adjustment. Hepatic impairment patients contraindicated for 25 mg losartan-containing doses.

Side-effects are usually mild. Symptomatic hypotension including dizziness may occur, particularly in patients with intravascular volume depletion (e.g. those taking high-dose diuretics). Hyperkalaemia occurs occasionally; angioedema has also been reported with some angiotensin-II receptor antagonists. Vertigo; less commonly gastro-intestinal disturbances, angina, palpitation, oedema, dyspnoea, headache, sleep disorders, malaise, urticaria, pruritus, rash; rarely hepatitis, atrial fibrillation, cerebrovascular accident, syncope, paraesthesia; also reported pancreatitis, anaphylaxis, cough, depression, erectile dysfunction, anaemia, thrombocytopenia, hyponatraemia, arthralgia, myalgia, renal impairment, rhabdomyolysis, tinnitus, photosensitivity, and vasculitis (including Henoch-Schonlein purpura)

Pregnancy Category D. Contraindicated in lactation. Angiotensin receptor blockers may cause fetal renal damage. Consider alternative therapies.

Monitor electrolytes (potassium, sodium) regularly. Maintain adequate hydration. Perform renal function tests (serum creatinine) every 3-6 months. Seek immediate care for hyperkalemia symptoms (muscle weakness, arrhythmia).

Elderly: Limit initial dose to 50/12.5 mg. Pediatrics: Safety unestablished. Renal disease: Avoid if CrCl <30 ml/min. Hepatic impairment: Avoid dose titration.

Losartan Potassium: Limited data are available in regard to overdosage in humans. The most likely manifestation of overdosage would be hypotension and tachycardia; bradycardia could occur from parasympathetic (vagal) stimulation. If symptomatic hypotension should occur, supportive treatment should be instituted. Neither losartan nor its metabolite can be removed by hemodialysis.

Hydrochlorothiazide: The most common signs and symptoms observed are those caused by electrolyte depletion (hypokalemia, hypochloremia, and dehydration resulting from excessive diuresis. If digitalis has also been administered, hypokalemia, may accentuate cardiac arrhythmias. The degree to which Hydrochlorothiazide is removed by hemodialysis has not been established.